Johnson & johnson strengthens neuroscience leadership with acquisition of intra-cellular therapies, inc.

New brunswick, n.j. & bedminster, n.j.--(business wire)--johnson & johnson (nyse: jnj) and intra-cellular therapies, inc. (nasdaq: itci) announced today that they have entered into a definitive agreement under which johnson & johnson will acquire all outstanding shares of intra-cellular therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, for $132.00 per share in cash for a total equity value.
ITCI Ratings Summary
ITCI Quant Ranking